Special issue of the Journal of Neuromuscular Diseases is devoted to the Treatabolome, designed to shorten diagnosis-to-treatment time for patients with rare diseases

In 2019, as part of the European Solve-RD project, Hanns Lochmüller, Gisèle Bonne and Rachel Thompson launched the Treatabolome, an initiative designed to extract details of effective treatments for rare diseases from the scientific literature and make them accessible through an online database that aims to allow patients to receive the right treatment for their condition as soon as they receive a genetic diagnosis.

The process of extracting reliable treatment information from scientific publications begins with a systematic review of the literature for each disease area to ensure that all the published information is captured. The Lochmüller Lab’s original systematic review of congenital myasthenic syndromes provided a comprehensive overview of the treatments available for these rare but often highly treatable diseases, which are one of our lab’s main focus areas.

This month, an open-access special issue of the Journal of Neuromuscular Diseases dedicated to the Treatabolome has been published. It includes six systematic reviews contributed by experts on rare neurological disorders, summarising the literature on each disease group and linking treatments with genotype and causative variants. Thanks to the team at CNAG in Barcelona behind the RD-Connect Genome-Phenome Analysis Platform, the data is also being transformed into an online database to be launched later this summer, which is intended to reduce treatment delays for patients with rare diseases by directly linking diagnosis and treatment information.

The special issue also includes a systematic review on the metabolic myopathies from our lab with Alex Manta, Sally Spendiff, Hanns Lochmüller and Rachel Thompson as co-authors.

You can find Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’  here.

Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’.
Manta A, Spendiff S, Lochmüller H, Thompson R.
J Neuromuscul Dis. 2021;8(3):401-417.
doi: 10.3233/JND-200621.
PMID: 33720849

 

Access the special issue of the Journal of Neuromuscular Diseases here.

Read the press release about the Treatabolome special issue here.

1by1treatabolome

Read next...

award winners

Celebrating Lab Members’ Recent Research Awards

We are thrilled to celebrate Kelly Ho for receiving first place for her poster presentation at this year’s American Society for Pharmacology and Experimental Therapeutics...
New publication - RTD (2)

Meet The Lochmüller Lab’s Newest Members!

Our research team is growing! We are excited to introduce three new members who have recently joined the Lochmüller lab and several students who will...
McMillan smart study (1)

New Clinical Study Examines Safety and Efficacy of IV Onasemnogene Abeparvovec in Broad SMA Cohort

Pediatric neurologist Dr Hugh McMillan publishes clinical study examining the safety and efficacy of IV onasemnogene abeparvovec in the broadest cohort of SMA patients to...
Text reading: Solve-RD publication: Solve-RD flagship publication: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Photos of Dr Kiran Polavarapu, Dr Rachel Thompson, Dr Hanns Lochmüller.

Solve-RD flagship publication in Nature Medicine: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Patients and families with rare disorders often remain without a genetic diagnosis despite modern advances in diagnostic testing. Due to the rarity and global distribution...
New publication: Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis . Author's photos on the right, diagram from paper underneath title.

New Lab Publication Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis

Rhabdomyolysis is an acute failure of cellular homeostasis characterized by acute skeletal muscle damage triggered by trauma, infection, drugs, or strenuous exercise. Recurrent rhabdomyolysis is...
New lab publication on riboflavin transporter deficiency model

New Publication: Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish

Riboflavin transporter deficiency (RTD) is a rare genetic disorder in children, characterised by progressive sensorimotor and cranial neuronopathy caused by mutations in riboflavin transporter protein-encoding...